111 related articles for article (PubMed ID: 7752176)
1. Metabolic effects of anti-hypertensive treatment with nifedipine or furosemide: a double-blind, cross-over study.
Lind L; Berne C; Pollare T; Lithell H
J Hum Hypertens; 1995 Feb; 9(2):137-41. PubMed ID: 7752176
[TBL] [Abstract][Full Text] [Related]
2. Prazosin GITS vs sustained release nifedipine in patients with hypertension and abnormal lipid profile: a randomized, controlled, multicenter study. Madras Hypertension Study Group.
Misra KP; Joglekar SJ; Mukherjee S; Nanivadekar AS
J Assoc Physicians India; 1998; Suppl 1():30-40. PubMed ID: 11233385
[TBL] [Abstract][Full Text] [Related]
3. Addition of urapidil or metoprolol to the treatment of hypertensive non-responders to nifedipine monotherapy: efficacy and metabolic effects. Italian Urapidil Study Group.
Zanchetti A
Blood Press Suppl; 1995; 3():38-46. PubMed ID: 8535541
[TBL] [Abstract][Full Text] [Related]
4. Moxonidine improves insulin sensitivity in insulin-resistant hypertensives.
Haenni A; Lithell H
J Hypertens Suppl; 1999 Aug; 17(3):S29-35. PubMed ID: 10489096
[TBL] [Abstract][Full Text] [Related]
5. Effects of selective alfa 1 and beta 1-adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity.
Andersson PE; Johansson J; Berne C; Lithell H
J Hum Hypertens; 1994 Mar; 8(3):219-26. PubMed ID: 8006923
[TBL] [Abstract][Full Text] [Related]
6. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine.
Agardh CD; Garcia-Puig J; Charbonnel B; Angelkort B; Barnett AH
J Hum Hypertens; 1996 Mar; 10(3):185-92. PubMed ID: 8733038
[TBL] [Abstract][Full Text] [Related]
7. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: a comparison with metformin.
Chazova I; Almazov VA; Shlyakhto E
Diabetes Obes Metab; 2006 Jul; 8(4):456-65. PubMed ID: 16776753
[TBL] [Abstract][Full Text] [Related]
8. Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors.
Aksnes TA; Reims HM; Guptha S; Moan A; Os I; Kjeldsen SE
J Hum Hypertens; 2006 Nov; 20(11):860-6. PubMed ID: 16988754
[TBL] [Abstract][Full Text] [Related]
9. [Does long-term blood pressure reduction in patients with essential hypertension improve concomitant metabolic disorders?].
Hauner H; Meissner C
Med Klin (Munich); 1994 Aug; 89(8):403-9. PubMed ID: 7968872
[TBL] [Abstract][Full Text] [Related]
10. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
[TBL] [Abstract][Full Text] [Related]
11. Is insulin resistance a predictor of the blood pressure response to anti-hypertensive treatment?
Lind L; Berne C; Andersson PE; Hänni A; Lithell H
J Hum Hypertens; 1995 Sep; 9(9):759-63. PubMed ID: 8551491
[TBL] [Abstract][Full Text] [Related]
12. Different effects of nifedipine and amlodipine on circulating catecholamine levels in essential hypertensive patients.
de Champlain J; Karas M; Nguyen P; Cartier P; Wistaff R; Toal CB; Nadeau R; Larochelle P
J Hypertens; 1998 Nov; 16(11):1357-69. PubMed ID: 9856375
[TBL] [Abstract][Full Text] [Related]
13. Lipids and cardiovascular reactivity changes in hypertensive cigarette smokers: enalapril versus nifedipine treatment effects.
Nazzaro P; Cicco G; Manzari M; Merlo M; Pirrelli A
Am J Med Sci; 1994 Feb; 307 Suppl 1():S150-3. PubMed ID: 8141156
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of insulin resistance in essential hypertension.
Lind L; Berne C; Lithell H
J Hypertens; 1995 Dec; 13(12 Pt 1):1457-62. PubMed ID: 8866908
[TBL] [Abstract][Full Text] [Related]
15. A double-blind, controlled, multicenter, randomized study comparing the antihypertensive effectiveness and tolerance of a daily dose of two nifedipine formulations: nifedipine microgranules versus nifedipine osmotic pump.
de Roa ER; Botero R; Octavio JA; Berrizbeitia ML; Mayorca E; Castro P; Miranda R; Valecillo E; Aroca G; Aza G; González M
Am J Ther; 2007; 14(2):140-6. PubMed ID: 17414581
[TBL] [Abstract][Full Text] [Related]
16. Effects of nilvadipine and amlodipine in patients with mild to moderate essential hypertension: a double blind, prospective, randomised clinical trial.
Leonetti G;
Curr Med Res Opin; 2005 Jun; 21(6):951-8. PubMed ID: 15969895
[TBL] [Abstract][Full Text] [Related]
17. Influence of the angiotensin II receptor antagonist losartan on diuretic-induced metabolic effects in elderly hypertensive patients: comparison with a calcium channel blocker.
Ohnishi K; Kohno M; Yukiiri K; Masugata H; Wada Y; Takagi Y; Ohmori K
Int J Clin Pharmacol Ther; 2001 Oct; 39(10):417-22. PubMed ID: 11680666
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
[TBL] [Abstract][Full Text] [Related]
19. Nifedipine vs. enalapril in treatment of hypertensive patients with glucose intolerance.
Andronico G; Piazza G; Mangano MT; Mule G; Carone MB; Cerasola G
J Cardiovasc Pharmacol; 1991; 18 Suppl 10():S52-4. PubMed ID: 1725004
[TBL] [Abstract][Full Text] [Related]
20. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
